Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., trading under the ticker DECA, is a clinical-stage biopharmaceutical company that came to market through a SPAC transaction and operates within the specialty pharmaceutical and pain-management sector. The company filed a Form 10-Q with the Securities and Exchange Commission on November 9, 2023, covering quarterly financial results as a post-combination public entity. Semnur's lead program focuses on non-opioid epidural steroid formulations targeting chronic and acute pain conditions. The SPAC vehicle associated with the DECA ticker completed its business combination, bringing Semnur into the public markets as part of a broader wave of healthcare-focused SPAC activity in the early 2020s. For full filing history, deal structure, and real-time SPAC data on DECA, sign up for complete access at SpacDesk.